HK Stock Market Move | InnoCare Pharma (09969) rose over 4% as strong growth in its commercialized products coupled with business development achievements led to a turnaround in profits in the first half of the year compared to the same period last year.

InnoCare Pharma (09969) rose more than 4%, and as of the time of this report, it increased by 4.21%, reaching HK$14.37, with a trading volume of HK$50.1133 million. In terms of news, InnoCare Pharma announced its interim results for 2026, reporting revenues of approximately RMB 1.137 billion, a year-on-year increase of 55.46%; adjusted profit of about RMB 277 million, turning losses into profits year on year; and profit attributable to the parent company of approximately RMB 246 million, also turning losses into profits compared to the previous year. The revenue growth was primarily attributed to strong growth in commercialized products and the realization of milestone values from global BD projects. In the first half of the year, revenue from pharmaceuticals reached RMB 920 million, a year-on-year increase of 43.2%, mainly benefiting from the continued rapid growth of Oubrektinib, as well as the new contributions from Tansyltumab and Lorlatinib. The announcement noted that during the reporting period, InnoCare Pharma further advanced its multi-product, multi-field strategy, with continued expansion in the fields of hematological oncology, autoimmune diseases, and solid tumors. Several assets have reached or are approaching key regulatory and clinical milestones, laying a solid foundation for sustained long-term growth.